Active situationHealthcareOngoing·Updated Apr 30, 2026·Published Jan 15, 2026
Penumbra / Boston Scientific — $15bn healthcare deal
PEN / BSX
$14.6bn strategic medtech combination in vascular intervention. FTC second request pending; EC review required.
CT
CTFN Editorial
Active Situations Desk · ctfn.news
Deal snapshot — free previewOngoing
Next event
Vote meeting
May 6, 2026· in 4d
CTFN estimated close
Nov 15, 2026
Key risks
FTC second request issued March 16 creates the primary timing and remedy risk — overlap in mechanical thrombectomy for VTE is the likely theory of harm.
Members only
Full intelligence on this situation
Subscribe to unlock CTFN analysis, regulatory lifecycle tracking, deal documents, shareholder activism, and proprietary closing estimates.
- Full CTFN editorial analysis + risk factors
- Per-regulator filing lifecycle with step tracking
- Shareholder activism + voting agreements
- Deal documents, advisors, key facts
- Watchlist alerts when situations move